Companies /Healthcare
Novavax Inc
NASDAQ: NVAX Biotechnology
$7.86
▼ $0.11 (−1.32%) today
Markets open · 10:50am ET

Novavax (NVAX) Earnings History & Trends

EPS and revenue vs. Street estimates · SEC filings
NVAX vs Market · 30-day return after each reportNVAXS&P 500
−20%0%+20%+8.1%+6.7%Q1 25+2.0%+2.5%Q2 25−12.3%+1.9%Q3 25−27.7%−8.3%Q4 25−7.9%+0.7%Q1 26+31.7%−0.3%Q2 26
−20%0%+20%Q1 25Q3 25Q1 26
NVAX EPS Trend · estimate vs actualEstimateActual
$0$2$0.71$2.93Q1 25$-0.08$0.62Q2 25$-0.92$-1.25Q3 25$-0.49$0.11Q4 25$-0.23$-0.06Q1 26$-0.38$-0.32Q2 26$-0.35$-0.19Q3 26
$0$2Q1 25Q3 25Q1 26Q3 26
NVAX Revenue Trend · estimate vs actualEstimateActual
$0$200.0M$400.0M$600.0M$343.9M$666.7MQ1 25$165.0M$239.2MQ2 25$44.9M$70.4MQ3 25$89.9M$147.1MQ4 25$81.0M$139.5MQ1 26$53.3M$56.7MQ2 26$50.4M$68.3MQ3 26
$0$200.0M$400.0M$600.0MQ1 25Q3 25Q1 26Q3 26

How Often Does Novavax Beat Earnings Estimates?

Novavax beat EPS estimates in 6 of its last 7 reported quarters, and has beaten 4 quarters in a row.

NVAX quarterly earnings per share and revenue versus Street estimates
Quarter EPS · est. Surprise Revenue · est. Surprise
Q3 2026 Quarter includes $11 million in non-cash deferred royalty recognition related to prior Nuvaxovid sales by SK bioscience to the South Korean government; no non-GAAP EPS disclosed. $-0.19 est. $-0.35 +45.09% $68.3M est. $50.4M +35.45%
Q2 2026 $-0.32 est. $-0.38 +16.58% $56.7M est. $53.3M +6.38%
Q1 2026 $-0.06 est. $-0.23 +73.46% $139.5M est. $81.0M +72.27%
Q4 2025 $0.11 est. $-0.49 +122.48% $147.1M est. $89.9M +63.75%
Q3 2025 $-1.25 est. $-0.92 −36.36% $70.4M est. $44.9M +56.99%
Q2 2025 $0.62 est. $-0.08 +895.89% $239.2M est. $165.0M +44.98%
Q1 2025 $2.93 est. $0.71 +313.55% $666.7M est. $343.9M +93.88%

Figures from SEC filings and company reports. Not investment advice.